Pay in 4 interest-free payments of $6.58 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
If BPC-157 was purchased today, the patent would likely expire in 2033 before the phase 1-2-3 trials would be completed, at which point all the generic manufacturers would be able to push the product on the back of all the hard work a pharmaceutical company can do (Im not sure if FDA approval would push the expiration of the patent back, but even then it would not be so financial lucrative)
doi:10.2105/ajph.84.5.783 Jay M, Gillespie C, Schlair S, Sherman S, Kalet A
A 2025 systematic review by Vasireddi and colleagues in HSS Journal screened 544 published papers and identified 36 meeting inclusion criteria 35 preclinical studies and only one human study: an uncontrolled, unblinded, retrospective case series of 12 patients receiving intra-articular BPC-157 for chronic knee pain, in which 7 of 12 (58%) reported self-described relief lasting more than 6 months, with no dose, effect size, or systematically collected adverse events published
E.et al (2016)
The patient exhibited no cerebral creatine along with high guanidinoacetate (GAA) concentrations in the brain and body fluids
